Long-term Monitoring and Health Priorities
At a Glance
Long-term care for aromatase deficiency focuses on protecting bone health, checking metabolism, recognizing ovarian torsion as an emergency, and discussing fertility. Monitoring with bone-density scans, selected blood tests, and specialist follow-up is individualized.
Living with aromatase deficiency requires a shift from “seeking a diagnosis” to “maintaining health.” Because this condition affects the body’s primary architectural and metabolic systems, long-term care focuses on protecting your bones, managing your metabolism, and watching for rare but serious physical changes.
Protecting Your Skeleton
Bone health is perhaps the most critical part of long-term monitoring. Estrogen is essential for building and maintaining bone mass. Without it, bones can remain thin and growth plates can stay open much longer than they should [1][2].
- DXA Scans: Doctors use Dual-Energy X-ray Absorptiometry (DXA) to measure bone mineral density. Your clinician will recommend an individualized schedule for DXA scans, as there is no single schedule for all ages [3][4]. Pediatric results should generally be reported with age- and size-adjusted Z-scores, and osteoporosis in children is not diagnosed from low bone density alone.
- Bone Age X-rays: Until the epiphyses (growth plates) are fully fused, your doctor will likely use clinician-selected X-rays of the hand and wrist to track skeletal maturity [2][5].
- The Puberty Window: Research shows that bone deficits can sometimes emerge during puberty even if measurements were normal in childhood, making this a high-priority time for monitoring [3].
Metabolic Health
Aromatase deficiency can influence how your body processes sugar and fat, though this varies significantly between individuals [6][4].
- Routine Screenings: Your medical team should periodically check your blood pressure, weight, and body mass index (BMI).
- Lab Monitoring: If metabolic surveillance is recommended by your clinician based on the limited condition-specific evidence, they may use fasting glucose and/or HbA1c to monitor insulin resistance, alongside lipid profiles to check cholesterol and triglycerides [4][2]. The frequency of these tests is individualized.
Emergency Signal: Ovarian Torsion
For 46,XX individuals, the most significant “red flag” involves the ovaries. About 43% of 46,XX patients in a review of reported cases developed ovarian cysts, which can grow quite large [2]. These cysts can cause the ovary to become heavy and unstable, leading to ovarian torsion.
This is a medical emergency. Torsion occurs when the ovary twists on its blood supply, which can lead to permanent damage if not treated immediately [7][8].
- The Warning Signs: Sudden, severe lower-abdominal or pelvic pain, often accompanied by nausea and vomiting [8][9].
- A Crucial Note: Sometimes the pain and nausea can go away for a short time and then return. A “lull” in symptoms does not mean the emergency has passed; you still need immediate medical evaluation [9].
- ACTION STATEMENT: New, persistent, worsening, recurrent, or severe pelvic/abdominal pain—especially if accompanied by nausea, vomiting, fainting, fever, or marked tenderness—requires urgent medical assessment at an emergency department.
Looking Toward the Future: Fertility
Fertility is a complex topic in aromatase deficiency, and research is still evolving.
- For 46,XX Patients: While many experience primary amenorrhea (no periods) without treatment, estrogen therapy along with cyclic progestogen commonly produces predictable withdrawal bleeding or uterine cycling [10][11]. This bleeding does not demonstrate normal ovarian function or ovulation, and reproductive potential remains uncertain [2][12].
- For 46,XY Patients: Outcomes are variable. Some individuals have been found to have azoospermia (absence of sperm), while others have maintained sperm production while receiving carefully managed estrogen therapy [13][14].
Because every person’s genetic mutation is unique, fertility should be discussed with a reproductive specialist who can perform individualized assessments of ovarian or testicular function, and mention timely fertility-preservation discussions such as semen cryopreservation or consultation about ovarian options when clinically appropriate [12][14].
Common questions in this guide
How often should I have a DXA bone-density scan with aromatase deficiency?
What do bone-age X-rays show in aromatase deficiency?
Which metabolic tests may be checked over time?
When does pelvic pain require emergency care with aromatase deficiency?
Can withdrawal bleeding after hormone therapy prove that I am ovulating?
How can fertility be assessed in aromatase deficiency?
How might ovarian cysts be monitored in aromatase deficiency?
Get notified when new evidence is published on Aromatase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Aromatase enzyme deficiency in an adult male patient and the effects of estrogen replacement therapy: a rare cause of tall stature.
Imre E, Akçay S, Yavuz DG
Hormones (Athens, Greece) 2025; (24(2)):525-532 doi:10.1007/s42000-025-00640-8.
PMID: 40048086 - 2
Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.
Fan L, Zhang B, Li L, Gong C
Clinical endocrinology 2020; (93(6)):687-695 doi:10.1111/cen.14277.
PMID: 32623730 - 3
Accelerated Pubertal Tempo in a 46,XY Aromatase-Deficient Patient.
Costanzo M, Garcia-Feyling J, Saraco N, et al.
Hormone research in paediatrics 2018; (90(4)):275-282 doi:10.1159/000492128.
PMID: 30173221 - 4
Aromatase deficiency in a male patient - Case report and review of the literature.
Miedlich SU, Karamooz N, Hammes SR
Bone 2016; (93()):181-186 doi:10.1016/j.bone.2016.09.024.
PMID: 27693882 - 5
Bone Disease Associated with Inactivating Aromatase Mutations and its Management.
Cavati G, Merlotti D, Cardamone P, et al.
Calcified tissue international 2025; (116(1)):14 doi:10.1007/s00223-024-01330-0.
PMID: 39751875 - 6
Late Recognition of Aromatase Deficiency Following 16 Years of Misdiagnosis as Congenital Adrenal Hyperplasia: A Case with Coexisting Gonadoblastoma and Dysgerminoma.
Alfadhli E, Turkistani A
Journal of clinical research in pediatric endocrinology 2026; doi:10.4274/jcrpe.galenos.2026.2026-6-8.
PMID: 42678028 - 7
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Praveen VP, Ladjouze A, Sauter KS, et al.
Journal of the Endocrine Society 2020; (4(4)):bvaa030 doi:10.1210/jendso/bvaa030.
PMID: 32318648 - 8
Ischemic Gangrene Requiring Right Salpingo-Oophorectomy in a Patient With Ovarian Cyst Torsion and a History of Bilateral Ovarian Cysts: A Case Report.
Doshi N, Kanani D, Garber L, et al.
Cureus 2025; (17(5)):e83595 doi:10.7759/cureus.83595.
PMID: 40476117 - 9
Ultrasonographic whirlpool sign in ovarian torsion with dual mature teratomas: A case report and literature review.
Varra FN, Fasoulopoulos A, Spathi E, et al.
Medicine international 2026; (6(4)):38 doi:10.3892/mi.2026.322.
PMID: 42200089 - 10
[A novel CYP19A1 variant causing aromatase deficiency in a family: case report and literature review].
Ren WQ, Sun XF, Xue Y, et al.
Zhonghua nei ke za zhi 2026; (65(9)):999-1004 doi:10.3760/cma.j.cn112138-20260210-00086.
PMID: 42733266 - 11
An Intron 9 CYP19 Gene Variant (IVS9+5G>A), Present in an Aromatase-Deficient Girl, Affects Normal Splicing and Is Also Present in Normal Human Steroidogenic Tissues.
Saraco N, Nesi-Franca S, Sainz R, et al.
Hormone research in paediatrics 2015; (84(4)):275-82 doi:10.1159/000437142.
PMID: 26279340 - 12
Ovarian and uterine development and hormonal feedback mechanism in a 46 XX patient with CYP19A1 deficiency under low dose estrogen replacement.
Burckhardt MA, Obmann V, Wolf R, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2015; (31(5)):349-54 doi:10.3109/09513590.2014.995619.
PMID: 25585547 - 13
Aromatase deficiency in a tall man: Case report of two novel mutations and review of literature.
Singhania P, Dash D, Dhar A, et al.
Bone reports 2022; (17()):101642 doi:10.1016/j.bonr.2022.101642.
PMID: 36504506 - 14
Congenital aromatase deficiency in an adult male: A case report of clinical course and symptom reversal with estrogen supplementation.
Coady P, Walia A, Hernandez B, et al.
Urology case reports 2026; (66()):103417 doi:10.1016/j.eucr.2026.103417.
PMID: 41908849
This page is for informational purposes only and does not constitute medical advice. Your endocrinology and reproductive-care teams should individualize monitoring, treatment, fertility counseling, and urgent evaluation for your situation.